{"id":1021700,"date":"2026-11-17T03:03:16","date_gmt":"2026-11-17T08:03:16","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/cancer-research-uk-and-dewpoint-therapeutics-partner-to-advance-potential-first-in-class-myc-condensate-modulator-into-clinical-development\/"},"modified":"2026-11-17T03:03:16","modified_gmt":"2026-11-17T08:03:16","slug":"cancer-research-uk-and-dewpoint-therapeutics-partner-to-advance-potential-first-in-class-myc-condensate-modulator-into-clinical-development","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/cancer-research-uk-and-dewpoint-therapeutics-partner-to-advance-potential-first-in-class-myc-condensate-modulator-into-clinical-development\/","title":{"rendered":"Cancer Research UK and Dewpoint Therapeutics partner to advance potential first-in-class MYC condensate modulator into clinical development"},"content":{"rendered":"<div class=\"mw_release\">\n<ul>\n<li>DPTX8743 is a potential first-in-class small molecule modulator of MYC condensates, targeting one of cancer\u2019s most important and historically undruggable drivers<\/li>\n<li>Cancer Research UK\u2019s Centre for Drug Development has agreed to fund, sponsor, and execute CTA-enabling studies and a Phase 1\/2a clinical trial; Dewpoint retains all rights to DPTX8743<\/li>\n<li>Collaboration aims to evaluate safety and establish clinical proof of concept for DPTX8743 across MYC-driven cancers with high unmet need\n<\/li>\n<\/ul>\n<p>LONDON and BOSTON, Nov.  17, 2026  (GLOBE NEWSWIRE) &#8212; Cancer Research UK and Dewpoint Therapeutics today announced a collaboration and licence agreement to advance DPTX8743, a potential first-in-class small molecule modulator of MYC condensates, into clinical development.<\/p>\n<p>Under the agreement, Cancer Research UK\u2019s Centre for Drug Development (CDD) is responsible for funding, sponsoring and executing a first-in-human Phase 1\/2a clinical trial of DPTX8743, including Clinical Trial Application (CTA)-enabling studies. Dewpoint retains all rights to DPTX8743 and has the right to license the results and intellectual property arising from the collaboration, with Cancer Research UK eligible to receive downstream milestone payments and royalties. Cancer Research Horizons, Cancer Research UK\u2019s innovation arm, will manage the commercial relationship between Cancer Research UK and Dewpoint.<\/p>\n<p>The collaboration represents an important step toward advancing a novel therapeutic approach to addressing MYC, one of oncology&#8217;s most validated yet historically difficult-to-drug targets, into clinical evaluation.<\/p>\n<p>DPTX8743 targets MYC biology through a novel mechanism designed to disrupt the transcriptional condensates that drive MYC-dependent gene expression. In preclinical models, DPTX8743 has demonstrated the ability to disrupt these condensates, suppress MYC-driven gene expression and induce tumour cell death.<\/p>\n<p>MYC is a critical driver of cancer, with abnormal MYC activity implicated in the majority of human cancers. Despite decades of research, MYC has proven extremely difficult to target and has historically been considered undruggable. By targeting the molecular processes that enable MYC activity, DPTX8743 has the potential to provide a new therapeutic approach for people with MYC-driven cancers, including ovarian, oesophageal, colorectal and pancreatic cancers.<\/p>\n<p>\n        <strong>Lars Erwig, Director of the CDD, said:<\/strong> \u201cMYC is one of the most important drivers of cancer, but it is notoriously difficult to target with drugs. DPTX8743 takes an innovative approach by targeting the condensate biology underlying MYC activity rather than the protein directly. We\u2019re excited to work with Dewpoint to advance this promising candidate into Phase 1\/2a development and investigate its potential for people with cancer.\u201d<\/p>\n<p>\n        <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=Gc2qa9EcsNIMGKF-vHdl7WLJRWvoqNCv5bEHwpm52LB9WENt30pvkaub_Bw9Bb3SVVMqIuKjU6ASxR5MfT_VcaN8RAslzd4UL0oGRrFjx14GnEYmj4oKDwdqK_rpT2WThnXEzBrP5JYvRhLbXCyXyg==\" rel=\"nofollow\" target=\"_blank\"><br \/>\n          <strong>Ameet Nathwani<\/strong><br \/>\n        <\/a><br \/>\n        <strong>, <\/strong><br \/>\n        <strong>Chief Executive Officer of Dewpoint Therapeutics,<\/strong><br \/>\n        <strong> said:<\/strong> \u201cWe are delighted to partner with Cancer Research UK, whose Centre for Drug Development brings world-class scientific and clinical expertise to advance DPTX8743 towards clinical proof of concept. Building on our clinical stage \u03b2-catenin programme, DPTX8743 extends our condensate approach to MYC, one of oncology\u2019s most important and historically challenging targets. This collaboration reinforces our conviction that condensate modulation can unlock new therapeutic possibilities for patients with significant unmet medical need.\u201d<\/p>\n<p>\n        <strong>About Cancer Research UK&#8217;s Centre for Drug Development<\/strong><br \/>\n        <br \/>Cancer Research UK has an impressive record of developing novel treatments for cancer. The Cancer Research UK Centre for Drug Development has been pioneering the development of new cancer treatments for 30 years. It has completed over 170 clinical trials designed to explore potential new anti-cancer agents in patients. Six of these new agents have made it to market, including temozolomide for brain cancer, abiraterone for prostate cancer and rucaparib for ovarian cancer.\u00a0<a href=\"https:\/\/www.globenewswire.com\/Tracker?data=k2SPD35w-xfkILFk7Y9tZaGDycdp-wxUWPHkKUqpTbdKJqejSIFe6i3mbWiTzySiNMl6DbODoo8UCO2yxF28tend-Yxnke5zA4wOqcXNo7s=\" rel=\"nofollow\" target=\"_blank\">www.cruk.org.uk\/cdd<\/a>\u00a0<\/p>\n<p>\n        <strong>About Dewpoint Therapeutics<\/strong><br \/>\n        <br \/>Dewpoint is a clinical-stage biotechnology company using its expertise to pioneer the development of condensate modulators. It aims to be the first-ever to develop and advance intentionally designed small-molecule condensate modulators for targets that have proven intractable with traditional approaches. Its proprietary c-mod discovery platform supports a pipeline spanning oncology, neurology, and cardiometabolic disease, with strategic collaborations including Bayer, Novo Nordisk, the Gates Foundation, and Cancer Research UK.<strong> Learn more at <\/strong><a href=\"https:\/\/www.globenewswire.com\/Tracker?data=YN_-unwjzFRC_GYeprcxuTTZeQzhJ5-ck-2mgb23FWZ4oMsnOGNdyIJrcGxvWD8V5YlR_mFLNJJAM07JneVvIA==\" rel=\"nofollow\" target=\"_blank\"><strong>Dewpointx.com<\/strong><\/a><strong> and follow us on <\/strong><a href=\"https:\/\/www.globenewswire.com\/Tracker?data=lOZdsQwVLfRppbFBMaRUIKLRi1dsOZmbDPG9B8pdv1pSECdU94EUgfksvhcd9q9XQSrMYA7xI0qExfNL-EnQtnAVga_pmQzF2jAYYByfLte0h0dwLr4DrPyjMdj_6Zwj\" rel=\"nofollow\" target=\"_blank\"><strong>LinkedIn<\/strong><\/a><strong>.<\/strong><\/p>\n<p>\n        <strong>Contacts<\/strong><br \/>\n        <br \/>Tim Bodicoat<br \/>Content Manager, Cancer Research UK<br \/>tim.bodicoat@cancer.org.uk<\/p>\n<p>\n        <strong>Dewpoint Media Contact<\/strong><br \/>\n        <br \/>media@dewpointx.com<\/p>\n<p>      <img decoding=\"async\" alt=\"\" class=\"__GNW8366DE3E__IMG\" src=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTg3OTAyMiM3OTY4OTc1IzIyOTE4NTU=\" \/><br \/>\n      <br \/>\n      <img decoding=\"async\" alt=\"\" src=\"https:\/\/ml.globenewswire.com\/media\/YmEzZjA0NjktN2UwNi00MmRiLThjM2ItYjFjYWM2YmUwNGE0LTEzMDM0MDUtMjAyNi0xMS0xNy1lbg==\/tiny\/Dewpoint-Therapeutics.png\" \/>\n    <\/div>\n<div class=\"mw_contactinfo\"><\/div>\n","protected":false},"excerpt":{"rendered":"<p>DPTX8743 is a potential first-in-class small molecule modulator of MYC condensates, targeting one of cancer\u2019s most important and historically undruggable drivers Cancer Research UK\u2019s Centre for Drug Development has agreed to fund, sponsor, and execute CTA-enabling studies and a Phase 1\/2a clinical trial; Dewpoint retains all rights to DPTX8743 Collaboration aims to evaluate safety and establish clinical proof of concept for DPTX8743 across MYC-driven cancers with high unmet need LONDON and BOSTON, Nov. 17, 2026 (GLOBE NEWSWIRE) &#8212; Cancer Research UK and Dewpoint Therapeutics today announced a collaboration and licence agreement to advance DPTX8743, a potential first-in-class small molecule modulator of MYC condensates, into clinical development. Under the agreement, Cancer Research UK\u2019s Centre for Drug Development (CDD) is responsible for &hellip; <\/p>\n<p class=\"link-more\"><a href=\"https:\/\/www.marketnewsdesk.com\/index.php\/cancer-research-uk-and-dewpoint-therapeutics-partner-to-advance-potential-first-in-class-myc-condensate-modulator-into-clinical-development\/\" class=\"more-link\">Continue reading<span class=\"screen-reader-text\"> &#8220;Cancer Research UK and Dewpoint Therapeutics partner to advance potential first-in-class MYC condensate modulator into clinical development&#8221;<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-1021700","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v28.8 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Cancer Research UK and Dewpoint Therapeutics partner to advance potential first-in-class MYC condensate modulator into clinical development - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/cancer-research-uk-and-dewpoint-therapeutics-partner-to-advance-potential-first-in-class-myc-condensate-modulator-into-clinical-development\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Cancer Research UK and Dewpoint Therapeutics partner to advance potential first-in-class MYC condensate modulator into clinical development - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"DPTX8743 is a potential first-in-class small molecule modulator of MYC condensates, targeting one of cancer\u2019s most important and historically undruggable drivers Cancer Research UK\u2019s Centre for Drug Development has agreed to fund, sponsor, and execute CTA-enabling studies and a Phase 1\/2a clinical trial; Dewpoint retains all rights to DPTX8743 Collaboration aims to evaluate safety and establish clinical proof of concept for DPTX8743 across MYC-driven cancers with high unmet need LONDON and BOSTON, Nov. 17, 2026 (GLOBE NEWSWIRE) &#8212; Cancer Research UK and Dewpoint Therapeutics today announced a collaboration and licence agreement to advance DPTX8743, a potential first-in-class small molecule modulator of MYC condensates, into clinical development. Under the agreement, Cancer Research UK\u2019s Centre for Drug Development (CDD) is responsible for &hellip; Continue reading &quot;Cancer Research UK and Dewpoint Therapeutics partner to advance potential first-in-class MYC condensate modulator into clinical development&quot;\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/cancer-research-uk-and-dewpoint-therapeutics-partner-to-advance-potential-first-in-class-myc-condensate-modulator-into-clinical-development\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2026-11-17T08:03:16+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTg3OTAyMiM3OTY4OTc1IzIyOTE4NTU=\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"3 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/cancer-research-uk-and-dewpoint-therapeutics-partner-to-advance-potential-first-in-class-myc-condensate-modulator-into-clinical-development\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/cancer-research-uk-and-dewpoint-therapeutics-partner-to-advance-potential-first-in-class-myc-condensate-modulator-into-clinical-development\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"Cancer Research UK and Dewpoint Therapeutics partner to advance potential first-in-class MYC condensate modulator into clinical development\",\"datePublished\":\"2026-11-17T08:03:16+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/cancer-research-uk-and-dewpoint-therapeutics-partner-to-advance-potential-first-in-class-myc-condensate-modulator-into-clinical-development\\\/\"},\"wordCount\":676,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/cancer-research-uk-and-dewpoint-therapeutics-partner-to-advance-potential-first-in-class-myc-condensate-modulator-into-clinical-development\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTg3OTAyMiM3OTY4OTc1IzIyOTE4NTU=\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/cancer-research-uk-and-dewpoint-therapeutics-partner-to-advance-potential-first-in-class-myc-condensate-modulator-into-clinical-development\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/cancer-research-uk-and-dewpoint-therapeutics-partner-to-advance-potential-first-in-class-myc-condensate-modulator-into-clinical-development\\\/\",\"name\":\"Cancer Research UK and Dewpoint Therapeutics partner to advance potential first-in-class MYC condensate modulator into clinical development - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/cancer-research-uk-and-dewpoint-therapeutics-partner-to-advance-potential-first-in-class-myc-condensate-modulator-into-clinical-development\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/cancer-research-uk-and-dewpoint-therapeutics-partner-to-advance-potential-first-in-class-myc-condensate-modulator-into-clinical-development\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTg3OTAyMiM3OTY4OTc1IzIyOTE4NTU=\",\"datePublished\":\"2026-11-17T08:03:16+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/cancer-research-uk-and-dewpoint-therapeutics-partner-to-advance-potential-first-in-class-myc-condensate-modulator-into-clinical-development\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/cancer-research-uk-and-dewpoint-therapeutics-partner-to-advance-potential-first-in-class-myc-condensate-modulator-into-clinical-development\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/cancer-research-uk-and-dewpoint-therapeutics-partner-to-advance-potential-first-in-class-myc-condensate-modulator-into-clinical-development\\\/#primaryimage\",\"url\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTg3OTAyMiM3OTY4OTc1IzIyOTE4NTU=\",\"contentUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTg3OTAyMiM3OTY4OTc1IzIyOTE4NTU=\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/cancer-research-uk-and-dewpoint-therapeutics-partner-to-advance-potential-first-in-class-myc-condensate-modulator-into-clinical-development\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Cancer Research UK and Dewpoint Therapeutics partner to advance potential first-in-class MYC condensate modulator into clinical development\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Cancer Research UK and Dewpoint Therapeutics partner to advance potential first-in-class MYC condensate modulator into clinical development - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/cancer-research-uk-and-dewpoint-therapeutics-partner-to-advance-potential-first-in-class-myc-condensate-modulator-into-clinical-development\/","og_locale":"en_US","og_type":"article","og_title":"Cancer Research UK and Dewpoint Therapeutics partner to advance potential first-in-class MYC condensate modulator into clinical development - Market Newsdesk","og_description":"DPTX8743 is a potential first-in-class small molecule modulator of MYC condensates, targeting one of cancer\u2019s most important and historically undruggable drivers Cancer Research UK\u2019s Centre for Drug Development has agreed to fund, sponsor, and execute CTA-enabling studies and a Phase 1\/2a clinical trial; Dewpoint retains all rights to DPTX8743 Collaboration aims to evaluate safety and establish clinical proof of concept for DPTX8743 across MYC-driven cancers with high unmet need LONDON and BOSTON, Nov. 17, 2026 (GLOBE NEWSWIRE) &#8212; Cancer Research UK and Dewpoint Therapeutics today announced a collaboration and licence agreement to advance DPTX8743, a potential first-in-class small molecule modulator of MYC condensates, into clinical development. Under the agreement, Cancer Research UK\u2019s Centre for Drug Development (CDD) is responsible for &hellip; Continue reading \"Cancer Research UK and Dewpoint Therapeutics partner to advance potential first-in-class MYC condensate modulator into clinical development\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/cancer-research-uk-and-dewpoint-therapeutics-partner-to-advance-potential-first-in-class-myc-condensate-modulator-into-clinical-development\/","og_site_name":"Market Newsdesk","article_published_time":"2026-11-17T08:03:16+00:00","og_image":[{"url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTg3OTAyMiM3OTY4OTc1IzIyOTE4NTU=","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"3 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/cancer-research-uk-and-dewpoint-therapeutics-partner-to-advance-potential-first-in-class-myc-condensate-modulator-into-clinical-development\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/cancer-research-uk-and-dewpoint-therapeutics-partner-to-advance-potential-first-in-class-myc-condensate-modulator-into-clinical-development\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"Cancer Research UK and Dewpoint Therapeutics partner to advance potential first-in-class MYC condensate modulator into clinical development","datePublished":"2026-11-17T08:03:16+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/cancer-research-uk-and-dewpoint-therapeutics-partner-to-advance-potential-first-in-class-myc-condensate-modulator-into-clinical-development\/"},"wordCount":676,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/cancer-research-uk-and-dewpoint-therapeutics-partner-to-advance-potential-first-in-class-myc-condensate-modulator-into-clinical-development\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTg3OTAyMiM3OTY4OTc1IzIyOTE4NTU=","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/cancer-research-uk-and-dewpoint-therapeutics-partner-to-advance-potential-first-in-class-myc-condensate-modulator-into-clinical-development\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/cancer-research-uk-and-dewpoint-therapeutics-partner-to-advance-potential-first-in-class-myc-condensate-modulator-into-clinical-development\/","name":"Cancer Research UK and Dewpoint Therapeutics partner to advance potential first-in-class MYC condensate modulator into clinical development - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/cancer-research-uk-and-dewpoint-therapeutics-partner-to-advance-potential-first-in-class-myc-condensate-modulator-into-clinical-development\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/cancer-research-uk-and-dewpoint-therapeutics-partner-to-advance-potential-first-in-class-myc-condensate-modulator-into-clinical-development\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTg3OTAyMiM3OTY4OTc1IzIyOTE4NTU=","datePublished":"2026-11-17T08:03:16+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/cancer-research-uk-and-dewpoint-therapeutics-partner-to-advance-potential-first-in-class-myc-condensate-modulator-into-clinical-development\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/cancer-research-uk-and-dewpoint-therapeutics-partner-to-advance-potential-first-in-class-myc-condensate-modulator-into-clinical-development\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/cancer-research-uk-and-dewpoint-therapeutics-partner-to-advance-potential-first-in-class-myc-condensate-modulator-into-clinical-development\/#primaryimage","url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTg3OTAyMiM3OTY4OTc1IzIyOTE4NTU=","contentUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTg3OTAyMiM3OTY4OTc1IzIyOTE4NTU="},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/cancer-research-uk-and-dewpoint-therapeutics-partner-to-advance-potential-first-in-class-myc-condensate-modulator-into-clinical-development\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"Cancer Research UK and Dewpoint Therapeutics partner to advance potential first-in-class MYC condensate modulator into clinical development"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/1021700","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=1021700"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/1021700\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=1021700"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=1021700"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=1021700"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}